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Abstract
Background: Aberrant signaling by ErbB-2 (HER 2, Neu), a member of the human Epidermal Growth Factor (EGF) receptor
family, is associated with an aggressive clinical behaviour of carcinomas, particularly breast tumors. Antibodies targeting the
ErbB-2 pathway are a preferred therapeutic option for patients with advanced breast cancer, but a worldwide deficit in the
manufacturing capacities of mammalian cell bioreactors is foreseen.
Methods: Herein, we describe a multi-platform approach for the production of recombinant Single chain Fragments of antibody
variable regions (ScFvs) to ErbB-2 that involves their functional expression in (a) bacteria, (b) transient as well as stable
transgenic tobacco plants, and (c) a newly developed cell-free transcription-translation system.
Results: An ScFv (ScFv800E6) was selected by cloning immunoglobulin sequences from murine hybridomas, and was expressed
and fully functional in all the expression platforms, thereby representing the first ScFv to ErbB-2 produced in hosts other than
bacteria and yeast. ScFv800E6 was optimized with respect to redox synthesis conditions. Different tags were introduced flanking
the ScFv800E6 backbone, with and without spacer arms, including a novel Strep II tag that outperforms conventional
streptavidin-based detection systems. ScFv800E6 was resistant to standard chemical radiolabeling procedures (i.e. Chloramine
T), displayed a binding ability extremely similar to that of the parental monovalent Fab' fragment, as well as a flow cytometry
performance and an equilibrium binding affinity (Ka approximately 2 × 108 M-1) only slightly lower than those of the parental
bivalent antibody, suggesting that its binding site is conserved as compared to that of the parental antibody molecule. ScFv800E6
was found to be compatible with routine reagents for immunohistochemical staining.
Conclusion: ScFv800E6 is a useful reagent for in vitro biochemical and immunodiagnostic applications in oncology, and a
candidate for future in vivo studies.
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The ErbB family of receptor tyrosine kinases includes four
members (ErbB-1 or HER-1 through ErbB-4 or HER-4)
that signal upon engagement in combinatorial dimeric
receptor combinations. ErbB-2 is the shared (and pre-
ferred) heterodimerization partner, and acts as the master
coordinator and integrator of signaling amplification.
Aberrant ErbB signaling is causally involved in the patho-
genesis of human tumors including astrocytomas, head
and neck squamous cell carcinomas, breast, ovary and
prostate cancers. ErbB-2 overexpression, most often
caused by gene amplification, can be detected by immu-
nohistochemistry in approximately 30% of breast carci-
nomas, is associated with an aggressive clinical course,
and predictive of a worse prognosis [1].
Antibodies to the ectodomain of the receptor molecule
have provided, among other approaches, a successful
strategy to target the ErbB-2 pathway [1]. A recombinant,
humanized antibody known as Trastuzumab-Herceptin®
was developed (reviewed in [1]), and is now regularly
included, alone and in combination with chemotherapy,
among the preferred therapeutic options for patients with
advanced breast cancer.
Although whole antibody expression in mammalian cells
results in the reliable production of industrial grade
recombinant products, it has at least three drawbacks:
safety (zoonotic diseases and oncogenic DNA sequences
might be inadvertently shuttled through recombinant
antibody preparations), size of the therapeutic molecule
(preventing tissue penetration), and cost (mammalian
cultures are very expensive bioreactors) [2,3]. In addition,
concerns have been raised that the foreseen expansion in
biopharmaceutical production will soon result in a world-
wide deficit in manufacturing capacity [2]. Alternative
production systems need to be actively explored.
Recombinant antibody fragments of small size, such as
minibodies, diabodies, and single chain fragments of var-
iable antibody regions (ScFvs) have been expressed in bac-
teria, yeast, plants [3-5] and, more recently, in prokaryotic
cell-free expression systems [6-9]. Although these expres-
sion platforms effectively address the problem of size
reduction, sequence reshuffling, in vitro synthesis, and
folding in non-physiological conditions may hamper the
binding efficiency of some recombinant antibodies. In
addition, the risk of endotoxin carryover and adverse reac-
tions to allergenic contaminants cannot be formally
excluded, particularly with recombinant protein prepara-
tions from prokaryotic systems.
Limitations notwithstanding, plants most effectively
address the problems of safety and cost, and are particu-
larly suited to process scale-up [2,3]. Unfortunately,
because 'molecular farming' is a very challenging task,
only a limited number of phytoantibodies have been
obtained so far, and only a few bear oncological interest
([10-12] and reviewed in [3]). To our knowledge, the only
available ScFv to ErbB-2 engineered for plant expression is
ScFv800E6, preliminarily characterized by us [13,14],
whereas other recombinant antibody fragments to ErbB-2
have been exclusively expressed in bacteria or yeast [15-
17].
Cell-free expression systems hold great promise for post-
genomic applications [7,9]. Recent refinements make it
also possible to produce bioactive, multiple disulfide-
bonded proteins [18], including recombinant antibodies
[6,9]. Their major limitation is the low yield reported by
some authors in early studies [6,8].
In summary, because there is no optimal expression plat-
form for the development and pharmacological use of
recombinant proteins, and there are no preset rules for
predicting whether or not a cloned immunoglobulin frag-
ment will be functionally expressed, an ideal approach to
the development of pharmaceutical-grade antibody frag-
ments must integrate the best of the available technolo-
gies, and each reagent has to be developed keeping in
mind versatility as the ultimate goal. In this report, we
describe our approach to the generation of a new series of
ScFv800E6 derivatives in expression systems alternative to
mammalian cell culture. We have extensively character-
ized these reagents to demonstrate that (quite unusually)
their binding efficiency is substantially unaffected by the
introduction of epitope tags and expression in bacteria,
plants, or a novel high-yield cell-free transcription-trans-
lation system that ensures disulfide link formation. It is
argued that versatility is a key feature that should be
actively selected, if recombinant antibodies are to be used
for biotechnological applications.
Methods
Cell lines and antibodies
The murine monoclonal antibodies (mAb) W6/800E6 (in
short, 800E6) and mAb 100A4, an IgG1 and IgG2a respec-
tively, bind two distinct polypeptide epitopes in the extra-
cellular portion of ErbB-2 [19]. They were used in all flow
cytometry experiments at optimal pre-determined dilu-
tions. Hybridoma 800E6 was used to clone Ig sequences.
MAb 100A4 was used as a control in some experiments.
The mAbs W6/32 and Ep3 [20] recognize class I Major
Histocompatibility antigens and a melanoma antigen,
respectively, and were also used as controls. ErbB-2 trans-
fectants and neoplastic cell lines (Table 1) were previously
characterized by others [21] and ourselves [19] for ErbB-2
expression. Monovalent Fab' fragments were prepared by
papain (Sigma-Aldrich St. Louis, MO, USA) digestion.Page 2 of 13
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The cloning of Variable Light (VL) and Variable Heavy
(VH) chain Ig sequences from the 800E6 hybridoma into
the pEMBL-ScFv800E6 and pHEN (for prokaryotic expres-
sion) vectors has been described [13]. The pEMBL-
ScFv800E6 plasmid was used to generate all the remaining
constructs, depicted in figure 1. For stable plant expres-
sion, a Hind III/Eco RI fragment was cloned into
pBG(dAbs)BIN (Fig. 1A). For transient plant expression, a
Hind III/Xho I fragment was filled in by the Polymerase
fragment unit (Pfu, Stratagene), and blunt end-ligated
into Sal I-linearized pP2C2S (Fig. 1B). For in vitro expres-
sion in transcription-translation systems, ScFv800E6
sequences from pEMBL-ScFv800E6 were PCR-amplified
and subcloned into pIVEX 2.1 and pIVEX 2.2 vectors
(Roche Applied Science), designed for the introduction of
Strep II (Strep) tags at either the N-terminus or C-terminus
(Fig. 1C and 1D). Fragments from pIVEX 2.1 and pIVEX
2.2 were excised and cloned into pIVEX 2.3d and pIVEX
2.4d to express polyhistidine (6XHis)-tagged ScFvs, (Fig.
1F and 1G). The two clones with C-terminal tags (Fig. 1C
and 1E) were then linearized with Xho I, blunted, and re-
Cloning strategy and map of ScFv 800E6 constructsFigure 1
Cloning strategy and map of ScFv 800E6 constructs. Diagram illustrating the construction of ScFvs for expression in 
plants (stable and transient expression: panels A and B, respectively), and in cell-free transcription-translation systems (C–G). 
A linker peptide sequence (Gly4Ser)3, multiple cloning sites (MCS), the T7 promoter, the IPTG-inducible pLac promoter, a 3' 
transcription terminator, a proteolytic cleavage site (Xa), a ribosome binding site (RBS), the Strep II and His-tags, the kanamy-
cin resistance NPT II gene, the 35S-CaMV promoter, the NOS terminator region for transcript stabilization, the RNA-depend-
ent RNA-polymerase binding site (RdRb), the viral movement proteins (M1, M2 and M3), and the viral coat protein (CP) are 
present in different plasmids. A synopsis of the different ScFvs and tag positions is provided in panel H.Page 3 of 13
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open reading frames. A construct with a 27 residue-long
spacer arm between the N-terminal His-tag and the cod-
ing sequence was produced by transferring the insert from
pEMBL-ScFv800E6 into the polylinker of pIVEX 2.4d
using Not I-Hind III adapters (Fig. 1G). The resulting
ScFvs are shown (Fig. 1H). A control ScFv with irrelevant
specificity (to Citrus Tristeza Virus, ScFvαCTV) was
expressed in bacteria [22].
Stable expression of ScFv800E6 in plants
Plant biology protocols were carried out as described [5],
according to standard procedures [23]. Stable expression
of ScFv800E6 in plants has been described [13]. Briefly,
bacterial cultures of the A. tumefaciens GV3101 strain har-
boring pBG(dAbs)BIN-ScF800E6 were used to transform
leaf disks from Nicotiana tabacum, and transgenic leaf
disks selected in the presence of kanamycin. One shoot
per leaf disk was grown in vitro in a climatic chamber, and
plant RNA was analyzed by RT-PCR for the expression of
VH sequences. Positive transgenic plants and their prog-
eny were grown in a containment greenhouse, leaf tissues
were homogenized [4], and total proteins were analyzed
by Western blot.
Transient expression of ScFv800E6 in plants
Nicotiana benthamiana plants were grown up to the 6
leaves state in a controlled greenhouse. In vitro transcripts
generated from 1 μg of Spe I-linearized pP2C2S-
ScFv800E6 were used for infection by rubbing leaves
dusted with celite [24]. Tissues were collected seven days
later, frozen in liquid nitrogen, and proteins were
extracted in 0.05 M Tris-HCl pH 8.0/0.3 M NaCl/0.01 M
PMSF/0.005 M ascorbic acid (5 ml per g of frozen tissue),
homogenized, sonicated at 100 Watts (3 times, 10" each),
ultra-filtered and concentrated (20×).
Transcription-translation of ScFv800E6 in vitro
The different pIVEX-ScFv800E6 proteins (Fig. 1H) were
expressed using the RTS 100 E. coli, a newly developed E.
coli cell-free expression system for disulfide bonded pro-
teins, according to the manufacturer's protocol (Roche
Applied Science), in a ProteoMaster instrument [25]. This
is based on the development, extensively described by
Kim and Swartz [18], of a transcription-translation system
involving several major novelties: (a) the inactivation of
disulfide-reducing activities contained in a standard E. coli
S30 extract, (b) the use of a glutathione redox buffer, (c)
pH optimization, (d) the addition of GroE chaperones,
and (e) a semi-continuous exchange dialysis format to
achieve longer expression reactions. A conventional,
reducing cell-free expression system was also used in con-
trol experiments. The UK construct and the E. coli chaper-
one DnaK are also from Roche. Brij 35 is from
Calbiochem/EMD Biosciences, San Diego, CA. His-tagged
ScFvs were purified by metal-chelate affinity chromatogra-
phy on Ni-NTA agarose columns (Qiagen).
ScFv testing
All ScFv preparations were tested for their ability to bind
ErbB-2+ cells by flow cytometry. The binding of ScFvs and
mAbs was revealed using fluorescein isothiocyanate
(FITC)-labeled rabbit antibodies to whole murine Ig
(Cappel/ICN, Aurora, OH) at 50 μg/ml in the second step,
unless noted otherwise. Where noted, antimurine Ig from
a different vendor (Dako, Glostrup, Denmark) was also
used. Phycoerythrin (PE)-conjugated Strep-Tactin was
from IBA (Goettingen, Germany). An ELISA binding assay
was carried out as follows: 96 well PVC microtiter plates
(Corning, Acton, MA) were coated overnight with purified
mAb 800E6, Fab' 800E6 and ScFv800E6 (approximately
equimolar concentrations of 6.0, 2.0 and 1.0 μg/ml,
respectively, in 0.1 M NaHCO3 pH 9.5). Following 3
washes with NaCl-tween (saline containing 0.05% Tween
20), adsorbed mAbs and fragments were incubated for 1
h with FITC-labeled rabbit antibodies to whole murine Ig
(50 μg/ml, e.g. the concentration used in immunofluores-
cence). After washing with NaCl-tween, binding of the
FITC-labelled antibody was revealed by 1 h incubation
with peroxidase-conjugated goat anti rabbit Ig (Cappel/
ICN), followed by washing and color development using
O-phenylenediamine (Sigma-Aldrich) as substrate. Cells
were metabolically labeled by incubation for 18 h in 35[S]-
methionine (3.7 MBq/ml) containing medium, solubi-
lized by the nonionic detergent NP40, and immunopre-
cipitated with protein A-sepharose 4B immunoadsorbents
(Amersham) pre-loaded with rabbit antimurine Ig and
either ScFvs or mAbs. Equilibrium binding studies were
performed by incubating affinity purified antibodies and
recombinant ScFvs (radiolabeled to a specific activity of
185 MBq/mg with 125I by the Chloramine T method) with
target cells (1 × 105 per well in 100 μl volumes) in mem-
brane-sealed 96 well plates (Millipore, Billerica, Ma)
allowing instantaneous removal of free ligands by vac-
uum manifold filtration. Values of bound and free ligands
were plotted according to the linear transform of the Law
of Mass equilibrium, and the best fit of experimental data
determined by regression analysis. All these procedures
and Scatchard plot analysis are described in detail else-
where [20].
Immunohistochemistry
Human breast carcinoma specimens were obtained in the
course of ablative surgery, in compliance with informed
consent procedures. Four μm frozen sections, fixed in cold
acetone for 10 min., were immunostained using a bioti-
nylated anti Ig secondary antibody, and a streptavidin-
biotin detection kit (Super Sensitive Detection Kit,
Menarini, Florence, Italy), and the samples were counter-
stained with Mayer hematoxylin.Page 4 of 13
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Specificity of ScFv800E6
Preliminary experiments were performed using crude bac-
terial lysates to compare the binding of ScFv800E6 and its
parental antibody, mAb 800E6. Both reagents bound
ErbB-2 transfectants but not parental ErbB-2-negative
cells, as expected, although the former was 7–10 times
weaker than the latter. An irrelevant ScFv to Citrus Tristeza
Virus (ScFvαCTV) did not stain either cell line (Fig. 2A and
2B). In spite of the different binding intensities, the two
reagents concordantly estimated ErbB-2 surface expres-
sion in a panel of breast carcinoma cell lines known [21]
to express a wide range of ErbB-2 levels (Table 1).
ScFv800E6 was titratable upon serial dilution (Fig. 2C),
further supporting its binding specificity. In addition,
ScFv800E6 and mAb 800E6 immunoprecipitated an iden-
tical 185 kD band from soluble extracts of metabolically
radiolabeled SK-BR-3 cells (Fig. 2D).
Flow cytometry and immunoprecipitation with ScFv 800E6 produced in E. coli and transgenic plantsigure 2
Flow cytometry and immunoprecipitation with ScFv 800E6 produced in E. coli and transgenic plants. Lysates (50 
μl) from bacteria expressing either ScFv800E6 or ScFvαCTV, and the parental mAb 800E6 were incubated with 32D-ErbB-2 
transfectants and ErbB-2-negative 32D cells (panels A and B, respectively), and revealed by an FITC-labeled antibody to whole 
murine Ig. Panel C: two-fold dilutions of bacterial lysates containing ScFv800E6 were tested as above on ErbB-2+ SK-BR-3 cells. 
ScFvαCTV and mAb 800E6 are reported for comparison. Panel D: metabolically radiolabeled SK-BR-3 cells were lysed and 
immunoprecipitated with the indicated antibodies and ScFvs. Asterisks mark a group of closely migrating background bands of 
unknown origin present in several lanes. These are unlikely to represent MHC class I heavy chains that are poorly, if at all, 
expressed by SK-BR-3 cells [30]. Panel E: Lysates (50 μl) from tobacco plantulas stably (stbl) or transiently (trns) expressing 
ScFv800E6, and from transiently mock-infected plants (as a representative negative control) were incubated with SK-BR-3 cells, 
and ScFv binding revealed by flow cytometry as above.Page 5 of 13
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plants
Upon stable plant transformation, RT-PCR of putative
transgenics revealed that 56% of them expressed
ScFv800E6 transcripts. Extracts from selected positive
plants were analyzed by Western blotting and estimated
to contain ScFv polypeptides at a concentration of 0.6–0.8
μg/g of plant tissue (not shown). Similarly, ScFv800E6
was detected by Western blot in extracts from both directly
and systemically infected leaves of transiently modified
Nicotiana benthamiana plants. Much higher yields (800
μg/g of plant tissue) were obtained from leaves exhibiting
systemic symptoms (data not shown). Extracts (50 μl)
containing 0.14 μg/ml and 160 μg/ml of ScFv800E6 from
stable and transient transgenic plants, respectively, were
used to stain SK-BR-3 cells in indirect immunofluores-
cence. A representative flow cytometry analysis at the
widely different antibody concentrations noted above
revealed that the two preparations similarly bound SK-BR-
3 cells (Fig. 2E). Binding intensities were comparable to
(or slightly lower than) the intensities seen with bacterial
extracts on the same target cells (compare panels C and E),
indicating that saturating concentrations of ScFv had been
reached. Quite puzzling, ScFv binding could not be
detected using an antibody to a c-Myc tag present on the
ScFvs produced in bacteria and plants (not shown), ham-
pering purification. Based on these findings, before
embarking on the production of additional transgenic
plants, we resorted to in vitro transcription-translation sys-
tems to rapidly obtain a set of modified ScFv800E6 pro-
teins to be used for the identification of optimal folding
conditions and for the evaluation of tagging and purifica-
tion strategies.
Expression of ScFv800E6 in cell-free in vitro transcription-
translation systems
ScFv800E6 constructs were prepared in 4 distinct pIVEX
vectors, each of which Strep- or His-tagged at the N- or C-
terminus (Fig. 1C–F), plus a fifth construct with a N-ter-
minal His-tag on the tip of a 27 residue-long spacer arm
(Fig. 1G). The Strep tag was selected because it is particu-
larly useful for flow cytometry detection, since it is recog-
nized with particularly high affinity by fluorescent,
recombinant Strep-Tactin. Because the ScFvs contain two
disulfide bonds, the five constructs were expressed not
only in a conventional E. coli-based cell-free transcription-
translation system, but also in a newly developed tran-
scription-translation system for disulfide-bonded pro-
teins. The control urokinase (UK) protein, that contains 6
disulfide bonds, was transcribed-translated in parallel.
Supernatants from representative His(6x)-ad-N-
ScFv800E6 transcription-translation mixtures were run on
a SDS-PAGE gel, and either stained by Coomassie blue
(Fig. 3A) or Western blotted by peroxidase-conjugated
antibodies to the His-tag and murine Ig (Fig. 3B). His(6x)-
ad-N-ScFv800E6 (solid black arrowheads: lanes 3, 4, 5,
15, 16 and 17) and UK (open white arrowheads: lanes 2
and 13) displayed the expected electrophoretic mobilities
(approximately 32 kD in both cases), and were absent in
lanes loaded with mock-transcribed-translated mixes
(lanes 1, 12, and 18). Neither the nonionic detergent Brij
35 (1%) nor the E. coli chaperone DnaK significantly
increased ScFv yield (compare lanes 3 and 4 to 5; 15 and
16 to 17; 21 and 22 to 23). In contrast, His(6x)-ad-N-
ScFv800E6 was barely detectable when translated in a
conventional, reducing system (lanes 14 and 20). Under
these conditions the ScFv could be mainly recovered in
the insoluble fractions (data not shown).
Table 1: Reactivity of ScFv 800E6 with ErbB-2 transfectants and human cell lines
Cell line Lineage CTVαScFv ScFv800E6 mAb 800E6 source/ref
32D Myelomonocyte Leukemia (murine) 71 7 7 [21]
32D-ErbB-2 Myelomonocyte Leukemia (transfectants) 6 171 2430
SK-BR-3 4 278 2256 ATCC/[21]
MDA-MB-361 3 60 399
ZR-75-1 Breast Ca 2 47 289
DAL1 8 44 155 our lab
MCF7 3 19 76 ATCC/[21]
T47D 2 18 50
End 9 Endometrial Ca 2 2 21 our lab
CRL1 Melanoma 6 7 10
BE Melanoma 1 2 20 [21]
ES-1 Melanoma 0 2 22
A431 Epidermoid Ca 0 0 10
SKOV3 Ovary Ca 1 1 10
1Mean fluorescence intensity (m.f.i.) values estimated by flow cytometry after subtraction of background staining in the presence of PBS + anti 
murine Ig-FITC (background m.f.i. ranged from 5 in 32D cells to 15 in the other cell lines). Cut-off levels can be arbitrarily set at values twice the 
highest background, e.g. above 15.Page 6 of 13
(page number not for citation purposes)
Journal of Translational Medicine 2006, 4:39 http://www.translational-medicine.com/content/4/1/39In comparison with the 31 kD molecular weight marker in
lane 8, the amounts of the ScFv component synthesized in
a disulfide-capable format (lane 5) could be estimated to
be approximately 1 μg of protein, which corresponds to a
concentration in reaction mixtures of 200 μg/ml, 10-fold
greater than that of most mAbs in hybridoma superna-
tants. The yield of the ScFvs was approximately 2.5% of
the total proteins contained in the mix at the end of the
transcription-translation process. All the ScFvs remained
soluble even after repeated (up to 3 times) freeze-thawing
cycles with no appreciable loss in reactivity (not shown).
Thus, considerable yields and enrichment can be obtained
Biochemical analysis of tagged ScFv 800E6 produced in a cell-free transcription-translation systemF gur  3
Biochemical analysis of tagged ScFv 800E6 produced in a cell-free transcription-translation system. Panel A: 
His(6x)-ad-N-ScFv800E6 and urokinase (UK) were transcribed-translated either in a conventional mix (disulfide -), or in a mix 
promoting disulfide bonding (disulfide +), as indicated, with and without Brij 35, or the chaperone DnaK. Transcription-transla-
tion was also carried out in parallel in the absence of template DNA. Supernatants (5 μl) of transcription-translation mixtures 
were run on a SDS-PAGE slab, side by side with two-fold dilutions of MW standards containing known amounts of a 31 kD 
protein, and the gel was stained by Coomassie blue. Panel B: Smaller volumes (1 μl) of the same supernatants were run as 
above, and electroblotted. The filter was stained with anti His-tag and anti Ig antibodies. Open and closed arrowheads mark 
UK and ScFv800E6 polypeptides.Page 7 of 13
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disulfide bonding of ScFv is ensured in vitro.
Flow cytometry with ScFvs produced in cell-free 
transcription-translation systems
To assess the activity and fine specificity of the ScFvs pro-
duced in the transcription-translation system, we tested
the ability of the parental mAbs and His(6x)-ad-N-
ScFv800E6 to inhibit each other in flow cytometry. Pre-
incubation of SK-BR-3 cells with a wide range of mAb
800E6 concentrations, but not mAb 100A4 to a distinct
ErbB-2 epitope [19], proportionally (and up to 95%)
inhibited the binding of His(6x)-ad-N-ScFv800E6 (Fig.
4A), with a clear prozone effect (a paradoxical reduction
of inhibition at high mAb concentrations) at 1 mg/ml.
Four selected points are also analytically displayed in
panel B. Lesser, but still significant, levels of competition
for the 800E6 epitope were seen when ScFv800E6 was
used in the pre-incubation step (not shown). Thus, the
binding of the disulfide-bridged ScFv can be competed by,
and retains the fine epitope specificity of, the parental
antibody.
All the 5 tagged pIVEX-ScFvs were transcribed-translated
in disulfide mixtures, and tested by flow cytometry at 5
different dilutions using the same FITC-labeled secondary
Comparative flow cytometry analysis of different ScFvs to ErbB-2 and epitope blockingFigure 4
Comparative flow cytometry analysis of different ScFvs to ErbB-2 and epitope blocking. Panel A: mAb 100A4 (0.1 
mg/ml) and mAb 800E6 (at the different, indicated concentrations) were incubated for 30 min with SK-BR-3 cells. His(6x)-ad-
N-ScFv800E6 from transcription-translation mixtures (at a final concentration of 1 μg/ml) was then added and tested for its 
ability to bind SK-BR-3 cells using a rabbit antibody to the His-tag followed by an FITC-labeled antibody to rabbit Ig. Binding of 
the His-tagged ScFv in the absence of competing antibody (no mAb), and background staining in the absence of ScFv (but in the 
presence of both anti His-tag and FITC-labeled antibodies; no ScFv) are also shown. Mean fluorescence intensities (m.f.i.). Four 
selected experimental points of the experiment in panel A (including maximal inhibition by mAb 800E6 at 0.1 mg/ml) are shown 
in panel B. Panel C: five-fold dilutions of the indicated ScFv and UK preparations were tested by flow cytometry for their ability 
to bind SK-BR-3 cells, and revealed by FITC-labeled anti Ig antibodies. Panel D: Strep-N-ScFv800E6, Strep-C-ScFv800E6, and a 
mock transcription-translation mixture (-) were tested in flow cytometry for their ability to bind SK-BR-3 cells using either PE-
Strep-Tactin or PE-streptavidin (thick and thin lines, respectively).Page 8 of 13
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cells with comparable efficiency and with a similar pro-
zone effect (Fig. 4C). The binding of all the ScFvs dis-
played the highest mean florescence intensity (m.f.i.)
value (140 approximately) at similar concentrations (in
the microgram per ml range). This concentration is equiv-
alent to 20 ng per 5 × 105 target cells. Two pIVEX-ScFvs
bearing a suitable tag (Strep-N-ScFv800E6 and Strep-C-
ScFv800E6) were also tested in flow cytometry using PE-
conjugated Strep-Tactin and PE-conjugated streptavidin as
secondary reagents (Fig. 4D). Four observations were
made: (a) the C-terminally tagged ScFv performed much
better than the N-terminally tagged one; (b) the fluores-
cence intensity conveyed by Strep-Tactin was in each case
much stronger than that conveyed by conventional
streptavidin, to the extent that the weak binding of Strep-
N-ScFv800E6 was essentially undetectable by the latter;
(c) the optimal combination (Strep-C-ScFv800E6 fol-
lowed by Strep-Tactin) resulted in a substantial improve-
ment in m.f.i. values as compared to the same ScFv
followed by antimurine Ig secondary reagents conjugated
with either FITC or PE (m.f.i of 700 vs. 140; compare with
Fig. 4C); (d) these m.f.i. values were closer to those typical
of the parental mAb 800E6 followed by conventional sec-
ondary antimurine Ig reagents conjugated with either
FITC or PE (m.f.i. values > 1300 in all the experiments that
were performed; see Fig. 2 and data not shown).
Similar to the strep II tag, a preference for C-terminal tag-
ging was also seen with His-tagged ScFvs and anti His sec-
ondary antibody, but the introduction of a spacer arm, as
in His(6x)-ad-N-ScFv800E6, restored the availability of
the N-terminal epitope tag (not shown). It can be con-
cluded that: (a) all the variants of ScFv800E6 can be pro-
duced in a cell-free system at concentrations and amounts
similar to those recommended for flow cytometry and
immunohistochemistry with most monoclonal antibod-
ies, (b) the type and position of the tags have no detecta-
ble effect on ScFv binding (i.e. tags do not interfere with
the antigen binding site), whereas the tag position is
important in order to make the tag available for secondary
reagents, and (c) Strep-Tactin outperforms streptavidin.
Thus, optimization in the position and type of tag, as well
as selection of appropriate secondary reagents, largely
compensate for the reduced performance of ScFvs in com-
parison to their parental mAb.
Conservation in the antigen binding site of ScFvs
We then addressed the issue of the reduced performance
of ScFvs in comparison to their parental mAb when eval-
uated by conventional secondary anti murine Ig reagents.
This may reflect one or more of the following: (a) a
reduced recognition by secondary antibodies due to the
removal of Fc epitopes from ScFv800E6; (b) a reduced
binding of the ScFv due to monovalency; (c) a reduced
binding performance of the ScFv due, among other possi-
ble causes, to any of the following: (i) alterations in cru-
cial amino acid sequences consequent to cloning
antibody sequences into an ScFv format; (ii). improper
folding of the antigen binding site upon in vitro transla-
tion of mammalian sequences in prokaryotic cell-free sys-
tems; (iii) ScFv dimerization.
To directly address (a), we tested the FITC-labeled anti-
body to whole mouse Ig used in flow cytometry for its
ability to bind mAb 800E6, its monovalent Fab' fragment
(as a control), and affinity-purified His(6x)-ad-N-
ScFv800E6, taking advantage of the ELISA assay described
in methods. The binding of FITC-labeled secondary anti-
bodies (from two different commercial sources, see meth-
ods) to mAb, Fab and ScFv adsorbed on PVC plates in
equimolar amounts displayed the following ratios:
10:5:1.
These results are consistent with the removal of some and
most framework Ig epitopes from the Fab' and ScFv,
respectively, and quantitatively agree with the 7–10 fold
difference in binding intensities between the ScFv and the
parental mAb, routinely detected in the above flow
cytometry studies. Having estimated their reactivity with
FITC-labeled secondary antibodies, the three reagents
were again compared, in the same flow cytometry experi-
ment, for their ability to bind SK-BR-3 cells. Optimal
working dilutions of the three reagents were determined
as shown in the experiments displayed in figures 2C and
4C to rule out the possibility of prozone effects, and stain-
ing was performed at the indicated, selected equimolar
concentrations. Representative results with mAb, one of
two preparations of Fab', and ScFv, followed by one of the
two FITC-labeled secondary antibodies that were
employed (Fig. 5A) revealed an approximately 10:1:1
ratio in the binding of the three reagents, with the Fab and
the ScFv displaying extremely similar binding intensities.
The ten-fold drop in the ScFv performance was confirmed,
and correlated with the ten-fold reduced recognition of
ScFv vs. mAb detected by the secondary antibody in the
ELISA binding assay. In contrast, the ten-fold drop in Fab'
performance exceeded the two-fold reduced recognition
by the secondary antibody.
These results altogether provide further support for (a),
and suggest that (b), e.g. reduced binding due to monova-
lent interactions, is also involved, although a more direct
method is needed to account for the different extent of
this reduction in the case of monovalent Fab' and ScFv.
Then, we directly measured the equilibrium binding affin-
ities of 125I-labeled mAb800E6, Fab' 800E6, and His(6x)-
ad-N-ScFv800E6, and determined the valence of the
parental mAb. Equilibrium binding studies demonstrated
a high binding affinity (Ka in the 108 M-1 range) for all thePage 9 of 13
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affinity of the ScFv and Fab' as compared to the parental
antibody. These were estimated to be approximately 3-
fold and 4.5-fold, respectively. A double number of ScFv
and Fab' as compared to mAb binding sites (intercept on
the abscissa) was consistent with mAb 800E6 being the
only reagents capable of bivalent interactions. Altogether,
the limited range of variation in the observed association
binding constants, and the detection of monovalent vs.
divalent binding demonstrated that the absence of Fc
epitopes (a) and monovalent binding (b) largely explain
the apparent low staining efficiency of ScFv800E6 when
using conventional secondary anti Ig reagents, whereas
alterations and/or mis-folding (c) of the ScFv play a
minor, if any, role in reducing its binding performance.
Finally, a comparison of Fab' and ScFv binding abilities in
different assays indicates that enzymatic fragmentation of
the natural antibody is more deleterious in our hands
than cloning and expression in a recombinant form of
ScFv800E6 sequences.
Use of ScFv800E6 for the immunohistochemical staining of 
breast cancer lesions
To provide evidence that recombinant ScFvs and phytoan-
tibodies may be useful in a diagnostic setting, semi-serial
cryostat sections of breast carcinoma lesions were stained
with different ScFv800E6 preparations. Representative
results (Fig. 6) demonstrate that all of them clearly and
reproducibly discriminated ErbB-2+ from ErbB-2- breast
carcinoma lesions.
Discussion
In this report we have exploited promising, alternative
expression systems to produce and test ScFv800E6 as a
candidate molecule for applications in oncology.
ScFv800E6 is the first ScFv to ErbB-2 produced in plants.
Along with its 5 tagged variants, it is also one of the few
ScFvs to be developed for expression in second-genera-
tion, high-yield, cell-free transcription-translation systems
capable of establishing disulfide link formation.
We have shown that the binding of ScFv800E6 obtained
from different platforms is antigen-specific, saturable,
titratable, and can be competed by the parental antibody,
i.e. it recapitulates the canonical features and the fine spe-
cificity of a natural ligand-target interaction. Radiobind-
ing studies and flow cytometry data were consistent with
a remarkably robust, stable, versatile, and modular
ScFv800E6 'backbone' that tolerates extensive modifica-
tions at both the N- and C-termini, although the position
of the tag is crucial for its availability upon incubation
with secondary reagents. The apparently low staining effi-
ciency of ScFv800E6 was largely due to the use of conven-
tional secondary anti-Ig reagents and not to a low binding
affinity, since ScFv binding, in flow cytometry, was at least
as high as that of the monovalent Fab' in spite of the use
of secondary reagent that preferentially bound to the lat-
ter. Accordingly, equilibrium binding studies revealed a
binding affinity slightly higher than that of the Fab' with
no major drop as compared to that of the parental, biva-
lent antibody. This is remarkable, since bivalent binding
Flow cytometry and Scatchard plot analysis with ScFv800E6 produced in anscription-translation systems and tobacco leavesigure 5
Flow cytometry and Scatchard plot analysis with 
ScFv800E6 produced in transcription-translation sys-
tems and tobacco leaves. Panel A: Equimolar amounts of 
His(6x)-ad-N-ScFv800E6, Fab' 800E6 and parental mAb 
800E6 were compared by flow cytometry for their ability to 
bind SK-BR-3, using a conventional FITC-labeled secondary 
antibody to whole murine Ig. Panel B: the binding of 125I-
labeled mAb 800E6 and His(6x)-ad-N-ScFv800E6 to SK-BR-3 
cells at equilibrium was expressed in the form of bound (B) 
ligand versus the ratio of bound over free (B/F) ligands. The 
slope of the best-fit curve of individual determinations is 
directly proportional to the observed binding affinity (Ka: 
association binding constant). The intercept on the abscissa is 
an extrapolation to infinity of the number of ErbB-2 epitopes 
per cell multiplied by the valence of the ligand.Page 10 of 13
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[26]. These results suggest that the antigen binding site of
the recombinant ScFv has undergone no major derange-
ments as compared to that of the natural antibody,
whereas enzymatic fragmentation may moderately ham-
per the performance of the Fab'. Thus, expression of
recombinant ScFv800E6 bypasses a potential obstacle
that would preclude size reduction of the parental 800E6
antibody.
ScFv800E6 can be produced in all the expression plat-
forms at concentrations (see below) sufficient, or greater
than required, for all the major indirect trace binding
assays, and all the ScFv variants perform satisfactorily with
no need to modify or adapt commercially available
immunodiagnostic reagents and kits (e.g. in immunohis-
tochemistry). ScFvs can be tagged for detection by an
extremely sensitive secondary reagent, such as Strep-Tac-
tin, that outperforms even sensitive streptavidin-based
detection systems and largely compensates for monova-
lent binding. ScFvs can be radiolabeled to high specific
activity for in vivo radioimaging by a standard Chloramine
T iodination, with no need for special procedures or ded-
icated protocols. In summary, ScFv800E6 variants are all
ready for application in oncology. In this respect, two
issues are of particular interest: yield and folding.
We observed that the yield of ScFv800E6 from stable
transgenic plants did not exceed the microgram per ml
range, i.e. it was low as compared to other ScFvs produced
Immunohistochemistry of breast carcinoma lesions with different preparations of ScFv800E6Figure 6
Immunohistochemistry of breast carcinoma lesions with different preparations of ScFv800E6. Semi-serial cryo-
static sections of a primary ductal breast carcinoma lesion were stained with (A) 50 μl of His(6x)-N-ScFv800E6 transcription-
translation mixes; (B) 50 μl of extracts from plants transiently expressing ScFv800E6; (C) 50 μl of extracts from wild-type 
plants; and (D) 50 μl of mAb 800E6 (50 μg/ml) in PBS/5% FCS. ScFv/mAb binding was revealed as described in Materials and 
Methods.Page 11 of 13
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improvement of three orders of magnitude was obtained
by recovering the ScFv800E6 from leaves exhibiting sys-
temic symptoms in transiently modified plants, indicat-
ing that the features of ScFv800E6 are not intrinsically
incompatible with its efficient expression in plants.
Because preliminary data indicate that transgene silencing
may affect ScFv expression in stable transgenic plants, we
are currently improving ScFv yield by taking advantage of
plant expression systems that alleviate this problem and
in addition dispatch antibody fragments to specific plant
compartments such as roots and seeds.
As an alternative to plant expression, we produced
ScF800E6 in a cell-free transcription-translation system
that, as described in methods, differs under several
respects from other cell-free systems previously used to
express disulfide-bonded ScFvs [6,8]. ScFv800E6 was
obtained with a yield of 200 μg/ml, approximately 20
times higher than that of a different ScFv produced in a
conventional format [6]. A systematic comparison involv-
ing transcription-translation of many different ScFvs in
the available formats is mandatory to determine whether
optimal conditions must be worked out individually for
every construct or, alternatively, similar protocols can be
used for different ScFvs.
Cell-free expression of ScFvs is also relevant in the context
of the 'ribosome display' approach. This approach takes
advantage of transcription-translation for the phenotypic
selection of ScFvs with increased affinity upon their
immobilization on polysomes [27,28]. In principle, it
should be possible to incorporate the present semi-con-
tinuous format in current ribosome display protocols,
offering a high-yield alternative to experiments aimed at
ScFv improvement.
A surprising finding becomes apparent when the results in
the various expression platforms are compared.
ScFv800E6 was functional when expressed in reducing
cytosolic environments (bacteria and plants), but not in
transcription-translation systems unable to establish
disulfide linkage (Figs. 3 and 4). At least two interpreta-
tions may be proposed: (a) some or all of the ScFv mole-
cules synthesized in vivo are functional because they
somehow manage to get disulfide-linked in the cytosol or
other cellular locations; (b) disulfide linkages are essential
in vitro but not in vivo, resulting in two different (but sim-
ilarly active) ScFv folds. These issues are of bio-technolog-
ical relevance in view of large-scale production. However,
to be addressed they require structural studies on large
amounts of purified ScFvs from different sources. What-
ever the exact folding mechanism, and the role of
disulfide linkage, ScFv800E6 is stable and active in differ-
ent expression platforms. This property is highly desirable
and unusual among previously described recombinant
antibody fragments [29]. This results in unique versatility
and flexibility in the choice of expression platforms.
Therefore, ScFv800E6 appears to be an ideal candidate for
a three-step development of bio-technological processes
leading to progressive improvement of the reagent. As
outlined in this report, reagents of this kind may be pre-
screened for activity in different hosts, modified and
tested on a small-medium scale in a convenient platform
(e.g. cell-free systems), and then moved (if required) to
another one (e.g. plants) for mass production, and the
optimization loop may be repeated as many times as
needed.
Plant and cell-free expression systems are largely comple-
mentary. The advantages of mass production of recom-
binant antibody fragments in plants have been long
known [3]. Now, with the production of functional ScFvs
in vitro, transcription-translation systems may also
become extremely attractive. In this respect, it may be
noted that although the available cell-free systems are
designed to produce amounts of recombinant proteins in
the milligram range, yield and final ScFv concentrations
in our experimental system exceed those contained in
hybridoma supernatants (Fig. 3). Moreover, scale-up is
not a concern, since there is no theoretical upper limit to
the reaction volume. This is in contrast to mammalian cell
bioreactors that require sophisticated equipments in
order to maintain adequate gas permeation and nutrient
diffusion in the liquid phase, and at the same time prevent
cell shearing.
Conclusion
By cutting down cost and initial investments, ScFv pro-
duction in alternative expression platforms may alleviate
the foreseen deficit in manufacturing capacity (bio-manu-
facturing bottleneck) of mammalian cell bioreactors, and
may become of special interest for a rapid translation of
potentially interesting bio-molecules into the clinical use.
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